Articles tagged with Vaccine Development
A new COVID-19 vaccine has been tested in humans, showing a good immune response and few side effects. The effectiveness of the vaccine is currently being investigated, but initial results suggest it could provide long-lasting immunity.
A new study provides evidence on when OAS occurs and how it impacts seasonal vaccines and booster shots. The findings suggest that boosting against a new strain can be effective if the new strain is sufficiently different from the previous one.
A new paper proposes sharing intellectual property rights to vaccines with the global community to increase access and potentially save millions of lives. By doing so, companies can raise prices for medicines under patents and sell them only to those willing to pay the most to maximize profits.
Researchers found that high levels of mucosal IgA antibodies in the airways protect against SARS-CoV-2 infection for at least eight months, with a 90% lower risk of re-infection. Participants with prior infections generated stronger mucosal immune responses to Omicron breakthrough infections.
Researchers explore challenges and propose next-generation vaccine strategies for mucosa-replicating viruses, which evade full immune response due to short incubation periods and nasal mucosa replication. To overcome immune tolerance, significant knowledge gaps must be filled on ideal vaccine formulations, dosage, and techniques.
A large study found that most symptoms of long COVID resolve within a year after a mild COVID-19 infection. Vaccinated people were at lower risk of breathing difficulties, the most common effect to develop after mild infection, compared with unvaccinated people.
A study published in Journal of Hepatology found that efficient priming of HBV-specific CD4 T cells is crucial for the success of therapeutic hepatitis B vaccination. The researchers developed a novel heterologous prime-boost vaccine, TherVacB, which induced antiviral efficacy in preclinical mouse models.
Researchers developed a CSIC vaccine that fully protects against SARS-CoV-2 infection in the brain and prevents associated brain damage. The MVA-CoV2-S vaccine candidate demonstrates sterilizing immunity and was effective even after reinfection with the virus.
The immunization program costs in low- and middle-income countries are driven mainly by the cost of delivery, with a funding gap projected to decline in the coming years. To bridge this gap, both national-level scale-up and resource mobilization are essential for improving vaccine financing.
Researchers at Brigham and Women's Hospital have developed a dual-action cell therapy approach to eliminate established tumors and induce long-term immunity. The vaccine, engineered using CRISPR-Cas9, is designed to kill tumor cells and stimulate the immune system to destroy primary tumors and prevent cancer recurrence.
A new three-dose malaria vaccine demonstrated safety and efficacy in adults living with endemic malaria in Burkina Faso, providing up to 48% protection. Researchers reduced the number of required injections from five shots to three while improving vaccine efficacy.
Texas Biomed is at the forefront of developing a Sudan ebolavirus vaccine and antibody therapeutic to combat the ongoing outbreak in Uganda. The Institute has been awarded millions of dollars in contracts to run studies required for FDA approval, utilizing its BSL-4 laboratory facilities.
The Ebola vaccine trials found all three regimens safe in both age groups, with antibody responses detectable for one year. The study enrolled over 3,100 volunteers in Guinea, Liberia, Sierra Leone, and Mali.
Researchers at La Jolla Institute for Immunology have confirmed that the smallpox vaccine MVA-BN (JYNNEOS) can teach T cells to recognize and fight the mpox virus. The study suggests that the JYNNEOS vaccine may provide protection against severe disease and could be effective in immunocompromised individuals.
Researchers at Scripps Research, IAVI, Fred Hutch, and VRC publish study data in Science, revealing a stepwise approach to producing antibodies capable of targeting wide range of HIV variants. The Phase 1 trial shows favorable safety profile and induces targeted response in 97% of vaccinated individuals.
Researchers have found that experimental vaccines, including a protein-based vaccine candidate with an adjuvant, provide superior protection against lung disease and higher levels of neutralizing antibodies compared to mRNA vaccines. The results inform the optimization and development of COVID-19 vaccines for young infant populations.
A global Phase 2/3 clinical trial found that vaccination with SCB-2019 reduced the risk of transmitting SARS-CoV-2 infection to household members. The study showed a significant reduction in symptomatic cases among vaccinated household contacts and indicated that vaccines can play an important role in controlling future outbreaks.
A new serological test, PepSeq, allows scientists to quickly test antibody binding against hundreds of thousands of protein targets, helping prepare for and respond to pandemics. The technology identifies specific antibodies that provide protection against infection, holding promise for developing effective vaccines and treatments.
Researchers found that antibodies against one of the two main domains of the SARS-CoV-2 viral entry machinery elicit a broad antibody response against many variants. This suggests strategies for clinical development of variant-resistant vaccines.
A new tablet-based vaccine has shown long-lasting protection against bacteria that cause urinary tract infections (UTIs) in mice. The vaccine was found to be comparable to antibiotics in efficacy, with durable antibody responses lasting for the lifetime of a mouse.
Biovac has concluded a licensing agreement with the International Vaccine Institute (IVI) to manufacture an oral cholera vaccine, addressing the critical shortage of vaccines needed to prevent cholera globally. The partnership aims to increase production volumes, reduce supply gaps, and support Africa's indigenous vaccine industry.
A new study published in PLOS Medicine found that COVID-19 vaccination provides significant protection against reinfection, with varying levels of effectiveness (60-94%) across different variants. The study analyzed data from over 200,000 people in Denmark and showed that vaccination offered up to 71% protection during the Alpha period...
Researchers have developed a new approach to stopping viral infections using a live-attenuated DNA virus vaccine. The method employs centanamycin to generate an altered virus that can't reproduce inside cells, stimulating the host's immune system to recognize and eliminate the invading virus particles.
The FDA's investigation into its own oversight of clinical trials reveals a concerning lack of surveillance, leaving room for scientific misconduct. Experts argue that the agency should inspect sites more frequently to ensure data quality and integrity.
Researchers have developed a new nasal vaccine that induces potent lung immunity and protects against SARS-CoV-2 infection in mice. The vaccine approach, which targets the nose, airways, and lungs, has shown promising results in preventing COVID-19 infection.
A team of scientists at Boston Children's Hospital created a new tool to analyze vaccine responses, enabling better understanding of immune system reactions. The Immune Signatures Data Resource contains data from 53 studies covering 24 different vaccines.
A research team developed a vaccine targeting synthetic opioid fentanyl to block its entry into the brain, preventing fatal effects. The breakthrough could have major implications for treating Opioid Use Disorder, with potential relapse prevention capabilities.
Researchers discovered Mycoplasma pneumoniae's lipids spur T cells to overproduce IL-17, leading to neutrophil recruitment and vaccine-enhanced disease. B cells also play a role in modulating the immune response, suggesting they may hold disease in check.
Researchers identified specific monkeypox mutations that contribute to its continued infectiousness. The virus is accumulating mutations where drugs and antibodies from vaccines are supposed to bind, making it smarter and more infectious.
A comprehensive review and meta-analysis found that young adults under 40 have a slightly elevated risk for myocarditis or pericarditis after mRNA COVID-19 vaccination. The analysis analyzed data from over 58 million participants and explored the relationship between COVID-19 vaccine and these rare but dangerous adverse reactions.
A new study led by Duke-NUS Medical School scientists found that inactivated SARS-CoV-2 vaccines elicit a broad immune response against different proteins on the virus, while mRNA vaccines stimulate a single spike protein response. This broader T-cell response may be beneficial in preventing severe COVID-19 disease.
A study published in The BMJ found a small increased risk of thrombosis with thrombocytopenia syndrome (TTS) after vaccination against the Covid-19 virus, particularly with adenovirus vaccines. Researchers recommend considering these risks when planning future immunization campaigns and vaccine development.
Researchers have developed an intranasal COVID-19 vaccine that works against the original virus and two variants, including omicron, in hamsters. The vaccine stimulates a strong immune response both systemically and in the respiratory tract.
A new study by the University of Waterloo found that individuals with anxiety disorders are not more hesitant to get vaccinated than those without. Instead, discomfort with uncertainty is a significant predictor of vaccine hesitancy in both anxious and non-anxious individuals.
Researchers developed a groundbreaking model to estimate bait vaccination effectiveness in wild animals by analyzing the proportion of immunized animals and vaccine applications. The study successfully tested the model using real data from Japan's CSF outbreak, demonstrating a measurable increase in immunized wild boars.
Two nonprofit research organizations partner to create new TB vaccine candidates with diverse adjuvant technologies and genetically diverse mouse models. The team aims to develop thermostable vaccines that can last for several months at room temperature or years in standard refrigerators.
A study of Russian adults found that those who accept vaccination unconditionaly are more likely to have higher trust in government and less frequent social media use. In contrast, vaccine rejectors tend to be more extroverted and friendly but less trusting of institutions.
Babies born during the pandemic were less likely to meet social communication developmental milestones, such as expressing a word or pointing, but more likely to crawl. Researchers suggest that lockdowns may have reduced language exposure and face-to-face interactions, leading to these delays.
The article highlights the need for a unified approach to prevent and respond to pandemics by adopting a One Health strategy. This involves targeted preparedness, drug and vaccine research, and worldwide cooperation on surveillance and stopping disease spread.
A novel COVID-19 vaccine developed by Brazilian scientists combines two SARS-CoV-2 proteins to trigger a cellular immune response. The vaccine, called SpiN, showed promise in animal trials, protecting against three strains of the virus and reducing viral load by up to 50 times.
A Rutgers-led study statistically evaluated government data to determine if COVID-19 vaccination increases the incidence of Guillain-Barré syndrome. The results show no significant association between any COVID-19 vaccinations and the disease.
Researchers develop custom vaccines that induce broadly neutralizing antibodies to protect against HIV variants. The team uses a modified HIV spike protein to prime the immune system, paving the way for an effective HIV vaccine.
Researchers developed a highly effective and safe Zika vaccine technology that prevents systemic infection in pregnant mice and stimulates an immunogenic reaction. The vaccine was tested in various mouse models, proving safe and protective against the virus.
A new scoring tool prioritizes countries with higher vaccination rates and vulnerable populations, aiming to allocate Covid-19 vaccines more fairly. The tool considers a broader range of factors than current global COVAX facilities, which have been criticized for insufficient access.
A study found that the 2021/22 influenza vaccine had only 36% effectiveness against A(H3N2) in Canada, with a mismatch between the vaccine strain and the circulating virus. This suggests that the replacement of the vaccine strain for the upcoming season is necessary.
Research finds strong association between enterovirus infection and type 1 diabetes; individuals with T1D eight times more likely to have an enterovirus infection than others. Vaccines aimed at preventing enterovirus infection may help prevent T1D development.
Researchers from NAU and University of Washington collaborate to create a safe and effective vaccine for Valley Fever, a fungal infection spreading due to climate change. The project aims to address the growing threat of emerging epidemics and prevent disease through vaccination.
A team of scientists from SMART and NTU Singapore has developed a rapid point-of-care test kit that measures antibodies against SARS-COV-2 and its variants, offering personalized vaccination strategies. The test kit requires just 10 minutes to show results and has up to 93% accuracy.
Researchers found that a 'slow delivery, escalating dose' vaccination strategy can prompt B cells to spend months mutating and evolving their antibodies, leading to more effective long-lasting vaccines. This breakthrough has implications for vaccines against pathogens like influenza, malaria, and SARS-CoV-2.
A global consortium has launched best practice surveillance protocols for Group A Streptococcus (Strep A) research, providing clear case definitions and guiding researchers in clinical trials. The new protocols aim to accelerate the development of a safe and effective Strep A vaccine.
Researchers have developed SARS-CoV-2 virus-like particles (VLPs) that can mimic the virus's behavior, allowing for safer vaccine development and testing. These VLPs could help scientists understand how the virus invades the central nervous system and potentially lead to more effective vaccines.
Researchers at Cleveland Clinic's FRIC found that cytoskeleton disruption is a key signal for the body to respond to viruses. This discovery has potential implications for developing new anti-viral vaccines and treatments.
Researchers at the University of Zurich have developed a new immunotherapy strategy to eliminate fibroblasts in targeted manner, reducing lung and liver fibrosis in mice. The treatment triggers an immune response via cytotoxic T-cells, eliminating activated connective tissue cells while leaving resting cells undamaged.
Researchers have developed a malaria vaccine candidate that is safe and immunogenic in adults, offering improved protection against the disease. The vaccine combines FMP013 antigen with ALFQ adjuvant, which displays promising immune-enhancing effects.
Researchers developed an AI method to predict how well new COVID-19 variants infect human cells and evade antibodies. The system can analyze a million mutated variants, enabling the development of next-generation antibody therapies and vaccines that provide broader protection against potential future variants.
Researchers analyzed COVID-19 lockdown strategies in Germany, Israel, and the US to determine optimal policy changes based on vaccine development timelines. Lockdowns were stricter before vaccine approval and continued to intensify after approval until vaccination reached a sufficient percentage.
A new Israeli study found that myocarditis cases were rare and mild after the third dose of Pfizer-BioNTech COVID-19 vaccine, with a risk of 1 in 15,000 among young males. The study's findings suggest potential explanations for the increased risk, including medical precautions and time between doses.
Experts argue that flawed narratives and premature scientific conclusions led to ineffective public health measures, care home deaths, and lax vaccination policies. The UK's response fell short of its potential, with a death toll approaching 200,000, due to a lack of evidence-based decision-making.
A new study finds that COVID-19 orphanhood is significantly higher in poorer countries due to pre-existing health and vaccine coverage inequity. The risk is driven by factors like poverty prevalence, lower GDP per capita, and non-communicable diseases.
A global study reveals that COVID-19 has led to a significant increase in orphaned children worldwide. The analysis, conducted by researchers at Australian National University, found that fertility rates, poverty, vaccine coverage, and disease prevalence contribute to the risk of children losing one or both parents during the pandemic.